This company listing is no longer active
9 Meters Biopharma Balance Sheet Health
Financial Health criteria checks 0/6
9 Meters Biopharma has a total shareholder equity of $-6.3M and total debt of $5.1M, which brings its debt-to-equity ratio to -80.5%. Its total assets and total liabilities are $9.3M and $15.6M respectively.
Key information
-80.5%
Debt to equity ratio
US$5.07m
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.94m |
| Equity | -US$6.30m |
| Total liabilities | US$15.61m |
| Total assets | US$9.31m |
Recent financial health updates
Recent updates
9 Meters Biopharma to execute 1-for-20 reverse stock split
Oct 179 Meters Biopharma GAAP EPS of -$0.04 in-line
Aug 159 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome
Jun 149 Meters drug effective in treating rare COVID-19 complication in children
May 269 Meters Bio gains 5% on Adage Capital stake disclosure
Dec 299 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications
Dec 219 Meters Bio launches equity offering
Dec 11Financial Position Analysis
Short Term Liabilities: NMTR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NMTR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NMTR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: NMTR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NMTR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NMTR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.4% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/18 22:50 |
| End of Day Share Price | 2023/07/18 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
9 Meters Biopharma, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |
| Jonathan Aschoff | B. Riley Wealth |